Stryker Corporation — FY 2018 Form 10-K
Business context and reporting period. Stryker is a global medical technology company selling orthopaedic, MedSurg, and neurotechnology and spine products in more than 80 countries. This filing covers the fiscal year ended December 31, 2018; it is an annual report, not a standalone fourth-quarter filing. Dollar amounts are in millions except per-share data.
Financial performance
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Net sales | $13,601 | $12,444 |
| Gross profit / margin | $8,938 / 65.7% | $8,180 / 65.7% |
| Operating income / margin | $2,537 / 18.7% | $2,297 / 18.5% |
| Net earnings | $3,553 | $1,020 |
| Diluted EPS | $9.34 | $2.68 |
| Operating cash flow | $2,610 | $1,559 |
| Capital expenditures | $572 | $598 |
| Cash, cash equivalents and current marketable securities | $3,699 | $2,793 |
| Total debt | $9,859 | $7,222 |
Reported sales grew 9.3% (9.0% in constant currency). Management attributed growth primarily to higher unit volumes, partly offset by lower prices. Segment sales were Orthopaedics $4,991 (+5.9%), MedSurg $6,045 (+8.8%), and Neurotechnology and Spine $2,565 (+18.0%).
Management reported adjusted net earnings of $2,779 and adjusted diluted EPS of $7.31, up 12.6% year over year. These are non-GAAP measures; the filing provides reconciliations and excludes specified acquisition, amortization, restructuring, recall, legal, regulatory, and tax items. Cash flow less capital expenditures was approximately $2,038.
Current assets exceeded current liabilities by $4,926 at year-end. The company reported $1,500 of borrowing capacity under its main credit facility and no commercial paper outstanding. Debt rose amid acquisitions and new note issuance; current maturities were $1,373.
Material changes versus the prior period
- Net earnings increased sharply, but the comparison is heavily affected by taxes: 2018 included a $1.5 billion non-cash tax benefit from transferring intellectual property between tax jurisdictions. The reported effective tax rate was negative 50.8%, versus 50.6% in 2017.
- FY 2018 included $2,451 of acquisition spending, chiefly K2M (approximately $1,380) and Entellus ($697). Neurotechnology and Spine sales growth was also acquisition-supported.
- Operating cash flow increased to $2,610, in part because recall-related payments were lower; working capital items (receivables, inventory and payables, net) consumed $329 of cash.
- Gross margin was flat at 65.7% as reported. Management’s adjusted gross margin declined to 66.0% from 66.3%, citing ASC 606 adoption and lower selling prices.
- For the fourth quarter, sales were $3,796 versus $3,471. Net earnings were $2,068 versus a $249 loss, primarily reflecting the tax benefit; diluted EPS was $5.44 versus a loss of $0.66.
Outlook, risks and unusual items
- Management’s stated objective is sales growth at the high end of the MedTech industry and a capital allocation priority of acquisitions, dividends, then share repurchases. The filing does not provide a clear numerical 2019 revenue or earnings forecast.
- The $1.5 billion intellectual-property-related tax benefit is non-cash in 2018; management expects the benefit to reduce cash taxes over nine years, with corresponding tax expense recognized over time.
- Product liability remains a key contingency. For Rejuvenate/ABG II and LFIT V40 recall matters, the estimated remaining probable loss range was approximately $255–$400; charges recorded reflect the minimum of that range. A November 2018 settlement covering many claims had confidential financial terms, and final costs could differ materially.
- Other risks include extensive and changing medical-device regulation, healthcare cost and pricing pressures, foreign-exchange exposure, cybersecurity and IT-system risks, supply concentration, and execution and integration of acquisitions. The EU Medical Device Regulation was scheduled to take effect in May 2020.
- Defined benefit pension plans were underfunded by $359. Uncertain income tax positions totaled $528, with resolution timing not reasonably estimable.
- The company adopted ASC 606 in 2018; management said its operating-results impact was not material and primarily involved reclassification of certain costs. The filing also disclosed planned adoption of lease accounting in 2019, with estimated right-of-use assets and lease liabilities of approximately $350.
Most important facts for investors to verify
- Separate underlying earnings growth from the $1.5 billion tax benefit and review the non-GAAP reconciliations and their recurring exclusions.
- Track the ultimate cost, cash payments, and resolution of the hip implant recall claims against the disclosed $255–$400 probable-loss range.
- Assess whether sales growth persists after acquisition contributions and ASC 606 effects, particularly in Neurotechnology and Spine.
- Monitor debt growth, near-term maturities, acquisition spending, and cash generation against dividends and repurchases.
- Follow tax-audit outcomes and realization of the deferred tax asset, as well as the pension funding position.
- Note that the auditor issued an unqualified opinion and management reported effective controls; however, internal-control evaluations excluded Entellus and K2M, which represented 8.3% of assets and 1.0% of 2018 sales.